Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

China-based United Laboratories International said on Monday it will license its weight-loss drug candidate to Danish ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40 Drug's pricing may limit accessibility in India, analyst says Novo's ...

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.

The European Medicines Agency (EMA) has advised that the drug can be used together with diet and physical activity to help ...

Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...